Abstract: A WAYNE293 LVPRO cell adapted to a serum-free medium environment, and applications thereof are provided. The human embryonic kidney cell WAYNE 293 is preserved in China General Microbiological Culture Collection Center (CGMCC) on May 24, 2021, the address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Yard, Beichen West Road, Chaoyang District, Beijing, the postal code is 100101, and the preservation number is CGMCC No. 22348. The human embryonic kidney cell WAYNE 293 may be derived from suspension culture of HEK293 cells in a serum-free medium free of an anti-agglomeration agent, has the characteristics of short doubling time, high growth density, high virus packaging efficiency, and is an important support for industrial development in the field of cell and gene therapy.

Abstract: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.

Abstract: The present invention provides a method for determining the nucleic acid composition in a total nucleic acid mixture comprising a first nucleic acid and a second nucleic acid. The method comprises: 1) treating the total nucleic acid mixture with a bisulfate, to convert the non-methylated cytosine in the total nucleic acid mixture into uracil, and obtain a converted total nucleic acid mixture; 2) subjecting the converted total nucleic acid mixture to multiplexed fluorescent quantitative PCR using a first set of amplification primers and a second set of amplification primers; and 3) based on the ratio R of the methylated amplification product to the non-methylated amplification product of the predetermined nucleic acid fragment, a methylation proportion M1 of the predetermined nucleic acid fragment in the first nucleic acid, and a methylation proportion M2 of the predetermined nucleic acid fragment in the second nucleic acid, determining the nucleic acid composition in the total nucleic acid mixture.

Abstract: The present invention provides a method for determining the nucleic acid composition in a total nucleic acid mixture comprising a first nucleic acid and a second nucleic acid. The method comprises: 1) treating the total nucleic acid mixture with a bisulfate, to convert the non-methylated cytosine in the total nucleic acid mixture into uracil, and obtain a converted total nucleic acid mixture; 2) subjecting the converted total nucleic acid mixture to multiplexed fluorescent quantitative PCR using a first set of amplification primers and a second set of amplification primers; and 3) based on the ratio R of the methylated amplification product to the non-methylated amplification product of the predetermined nucleic acid fragment, a methylation proportion M1 of the predetermined nucleic acid fragment in the first nucleic acid, and a methylation proportion M2 of the predetermined nucleic acid fragment in the second nucleic acid, determining the nucleic acid composition in the total nucleic acid mixture.

Abstract: Provided are a method, system, and computer-readable medium for determining whether a copy number variation exists in a sample genome. The method includes sequencing a sample genome to obtain a sequencing result formed by multiple reads; comparing the sequencing result with a reference genome sequence to determine the distribution of the reads on the reference genome sequence; determining, based on the distribution of the reads on the reference genome sequence, multiple breakpoints on the reference genome sequence, wherein the number of the reads on either side of each breakpoint are significantly different; determining, based on the plurality of breakpoints, a detection window on the reference genome; determining, based on the reads falling in the detection window, a parameter; and determining, based on the difference between the first parameter and a preset threshold, whether a copy number variation exists in the sample genome against the detection window.

Abstract: The present invention relates to a method for detecting genetic variation, comprising the following steps: acquiring reads from a test sample; aligning said reads with a reference genome sequence; dividing said reference genome sequence into windows, calculating the number of said reads which are aligned to each window, and acquiring the statistic for each window on the basis of the number of said reads; and for a fragment of the reference genome sequence, acquiring the genetic variation sites on the basis of the change in the statistics of all the windows thereon in the fragment of the reference genome sequence.

Abstract: The present invention relates to the field of genomic mutation detection, and in particular, to the detection of the copy number variation (CNV) in cellular chromosomal DNA fragments. The present invention also relates to the detection of diseases related to the copy number variation in the cellular chromosomal DNA fragments.

Abstract: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.